Structure Therapeutics (GPCR) Depreciation & Amortization (CF) (2022 - 2026)

Structure Therapeutics' Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $576000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 110.22% year-over-year to $576000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 55.42% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 33.3% from the prior year.
• Depreciation & Amortization (CF) climbed to $576000.0 in Q1 2026 per GPCR's latest filing, from $412000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $576000.0 in Q1 2026 and bottomed at $59000.0 in Q2 2022.
• The 5-year median for Depreciation & Amortization (CF) is $222000.0 (2024), against an average of $204764.7.
• Across the five-year window, Depreciation & Amortization (CF) changed 0.0% in 2023 and surged 290.28% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $72000.0 in 2022, then changed by 0.0% to $72000.0 in 2023, then jumped by 290.28% to $281000.0 in 2024, then surged by 46.62% to $412000.0 in 2025, then jumped by 39.81% to $576000.0 in 2026.
• Per Business Quant, the three latest GPCR Depreciation & Amortization (CF) figures stand at $576000.0 (Q1 2026), $412000.0 (Q4 2025), and $356000.0 (Q3 2025).